Professional Information Dr.McGill University Comments In TDP-43 Proteinopathy, Misplaced PolyA Tails Mean Crippled Retromers 13 Jan 2026 ...

According to a recent study, the view that Alzheimer’s disease damages the brain irreversibly might need to change. In December 22 Cell Reports Medicine online, scientists led by Andrew Pieper of Case ...

A community cohort boasting 16,000 participants? A memory clinic that sees more than 2,000 patients per month? A countrywide goal of screening 80 percent of its aged population for AD? These are a few ...

The dbl-PAC-Tg(SNCA A53T) +/+;Snca-/-model, referred to here as double-transgenic mice, are mice lacking endogenous α-synuclein (Snca knockout mice) that were crossed with two homozygous transgenic ...

With two amyloid immunotherapies on the market in many countries, scientists are eager for information on how durable their clinical effects will be. At this year’s Alzheimer’s Association ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease pathology with remarkable accuracy (see Part 7 of this series). How ...

Austria’s beautiful capital city of Vienna hosted the 19th International Conference on Alzheimer’s and Parkinson’s diseases, which drew a record 5,554 attendees from 76 countries. From April 1 to 5, ...

As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...

This letter was prompted by your recent perspective paper and the responses it provoked in an Alzforum discussion. Generally, my comments are offered with the intellectual humility required when ...

Just as Eisai notches wins in its campaign for lecanemab approval around the world—last month in the European Union, this week in Mexico—a dozen research and clinical leaders called on the U.S. FDA ...

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...